trending Market Intelligence /marketintelligence/en/news-insights/trending/xcdtapzt0wlx0emmbaqhrq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Swedish Parkinson's drug developer Lobsor Pharmaceuticals considers IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Swedish Parkinson's drug developer Lobsor Pharmaceuticals considers IPO

Swedish startup Lobsor Pharmaceuticals AB, which has developed a product to compete against AbbVie Inc.'s Parkinson's medicine Duodopa, is considering going public, Bloomberg News reported.

In an interview, the drugmaker's chairman, Ulf Rosen, told Bloomberg that the drugmaker is considering a variety of options, including an IPO on Stockholm's First North Premium marketplace. It may also raise cash through private equity or tap into existing funds and expected revenue from the sales of Lecigon to expand its business.

Lecigon was recently approved by the Swedish Medical Products Agency to treat the symptoms of Parkison's — which has no cure — and the company is seeking funds to accelerate the process of commercialization, starting with the Nordic region. With further plans to expand throughout Europe and the U.S., Rosen told Bloomberg that the company would like to "better understand initial traction in the market" before deciding on a course of action.

The product will compete against Abbvie's Duodopa, which dominates the market for intestinal infusion and raked in about $355 million in revenues during 2017, an increase of 21.1% year over year. The medicine, administered via a pump, is approved in U.S., Europe and Japan, and generated $211 million in sales during the first half of 2018, up 31%, compare to first half of 2017.